Bioequivalence Study of Sulfadoxine/Pyrimethamine 500/25 mg Dispersible Tablet

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

August 31, 2024

Study Completion Date

September 30, 2024

Conditions
Fasting
Interventions
DRUG

Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets.

The 500/25 mg sulfadoxine/pyrimethamine tablet will be dispersed in approximately 10 mL of water in a cup, the mixture obtained will be shaken thoroughly and given immediately to the subject to drink the contents, then the cup will be rinsed with additional approximately 10 mL of water and have the subject drink the contents to assure that the whole dose is taken.

DRUG

Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets in SPAQ

The 500/25 mg sulfadoxine/pyrimethamine tablet will be dispersed in approximately 10 mL of water in a cup, the mixture obtained will be shaken thoroughly and given immediately to the subject to drink the contents, then the cup will be rinsed with additional approximately 10 mL of water and have the subject drink the contents to assure that the whole dose is taken.

Trial Locations (1)

11196

International Pharmaceutical Research Center (IPRC) Queen Rania Street - Sport City Circle,, Amman

All Listed Sponsors
collaborator

Medicines for Malaria Venture

OTHER

lead

Swiss Pharma Nigeria Limited

INDUSTRY

NCT06522763 - Bioequivalence Study of Sulfadoxine/Pyrimethamine 500/25 mg Dispersible Tablet | Biotech Hunter | Biotech Hunter